{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T02:16:42Z","timestamp":1793931402249,"version":"4.8.0"},"reference-count":25,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"3","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2022,5]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>Despite the effectiveness of several biological agents in the treatment of inflammatory bowel disease (IBD), some patients respond better than others. Such discrepancies are often evident early in the treatment course. The aim of this study is to identify the risks and assess the rate of early biological discontinuation (BD) among IBD patients.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>In this retrospective cohort study conducted in Bahrain all IBD patients who were administered biological agents between June 2009 and June 2019 were included. Medical records were reviewed to collect study data and confirm IBD diagnoses. Early discontinuation of biological agents was defined by discontinuation of a biological agent (within 6 months from administration). Montreal classification was used to classify Crohn's disease and ulcerative colitis (UC) according to location and extension, respectively.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>\n                      Ineffectiveness was the most common reason for early BD. Early BD was not related to the type of IBD, biological agent used, or to most patient-related factors (such as gender and family history). Patient age at index biological initiation was the only independent significant predictor of early BD (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = 0.045, adjusted odds ratios (95% CI): 1.06 (1.001\u20131.116)] even after correction of two significant factors: comorbid diabetes and marked weight loss at diagnosis.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>The older the IBD patient at the time of biological therapy initiation, the higher the incidence of early BD. Therefore, caution and close follow-up are required for biological therapy among elderly patients to assess effectiveness and adverse drug reactions.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.4103\/sjg.sjg_336_21","type":"journal-article","created":{"date-parts":[[2022,1,25]],"date-time":"2022-01-25T04:14:52Z","timestamp":1643084092000},"page":"193-200","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":5,"title":["Early discontinuation of biological therapy among inflammatory bowel disease patients in Bahrain"],"prefix":"10.4103","volume":"28","author":[{"given":"Maheeba","family":"Abdulla","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jehad","family":"AlQamish","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nafeesa","family":"Mohammed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mahmood","family":"Al Saeed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hasan Jawad Al","family":"Aali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aysha","family":"Al Khaja","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zahra Abdulla Isa Yusuf","family":"Hasan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fatema Yusuf","family":"Haider","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sayed Dhiyaa Noor","family":"Ebrahim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zahra Sayed Alawi","family":"Mahfoodh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mahmood Ali Hasan","family":"Hubail","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isa","family":"Alhajri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fatema","family":"Al-Matrook","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmed","family":"Tork","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-5-20240829","doi-asserted-by":"crossref","first-page":"1590","DOI":"10.1016\/S0140-6736(12)60026-9","article-title":"Crohn's disease","volume":"380","author":"Baumgart","year":"2012","journal-title":"Lancet (London, England"},{"key":"R2-5-20240829","doi-asserted-by":"crossref","first-page":"1606","DOI":"10.1016\/S0140-6736(12)60150-0","article-title":"Ulcerative colitis","volume":"380","author":"Ordas","year":"2012","journal-title":"Lancet (London, England"},{"key":"R3-5-20240829","doi-asserted-by":"crossref","first-page":"133","DOI":"10.2147\/CEG.S127909","article-title":"Inflammatory bowel disease in Bahrain: Single-center experience","volume":"10","author":"Abdulla","year":"2017","journal-title":"Clin Exp Gastroenterol"},{"key":"R4-5-20240829","doi-asserted-by":"crossref","first-page":"1178","DOI":"10.1136\/gut.2010.234617","article-title":"Surgery for adult Crohn's disease: What is the actual risk","volume":"60","author":"Bouguen","year":"2011","journal-title":"Gut"},{"key":"R5-5-20240829","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/0016-5085(94)90054-X","article-title":"Course of ulcerative colitis: Analysis of changes in disease activity over years","volume":"107","author":"Langholz","year":"1994","journal-title":"Gastroenterology"},{"key":"R6-5-20240829","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1056\/NEJMoa0904492","article-title":"Infliximab, azathioprine, or combination therapy for Crohn's disease","volume":"362","author":"Colombel","year":"2010","journal-title":"N Engl J Med"},{"key":"R7-5-20240829","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1053\/j.gastro.2013.10.052","article-title":"Combination therapy with infliximab and azathioprine is superior to monotherapy with either agent in ulcerative colitis","volume":"146","author":"Panaccione","year":"2014","journal-title":"Gastroenterology"},{"key":"R8-5-20240829","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1136\/gut.40.4.443","article-title":"Tumour necrosis factor and Crohn's disease","volume":"40","author":"Van Deventer","year":"1997","journal-title":"Gut"},{"key":"R9-5-20240829","doi-asserted-by":"crossref","first-page":"3350","DOI":"10.4049\/jimmunol.149.10.3350","article-title":"Antiviral activity of tumor necrosis factor is signaled through the 55-kDa type I TNF receptor [corrected]","volume":"149","author":"Wong","year":"1992","journal-title":"J Immunol (Baltimore, Md: 1950"},{"key":"R10-5-20240829","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.1056\/NEJMoa1606910","article-title":"Tofacitinib as induction and maintenance therapy for ulcerative colitis","volume":"376","author":"Sandborn","year":"2017","journal-title":"N Engl J Med"},{"key":"R11-5-20240829","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1016\/j.gtc.2017.05.012","article-title":"Use of anti-tumor necrosis factors and anti-integrins in the treatment of Crohn's disease","volume":"46","author":"Shivashankar","year":"2017","journal-title":"Gastroenterol Clin North Am"},{"key":"R12-5-20240829","doi-asserted-by":"crossref","first-page":"215","DOI":"10.2147\/JIR.S165330","article-title":"Role of biologics and biosimilars in inflammatory bowel disease: Current trends and future perspectives","volume":"11","author":"Rawla","year":"2018","journal-title":"J Inflamm Res"},{"key":"R13-5-20240829","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1136\/gut.2005.082909","article-title":"The Montreal classification of inflammatory bowel disease: Controversies, consensus, and implications","volume":"55","author":"Satsangi","year":"2006","journal-title":"Gut"},{"key":"R14-5-20240829","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1093\/bmb\/ldp036","article-title":"The implications of anti-tumour necrosis factor therapy for viral infection in patients with inflammatory bowel disease","volume":"92","author":"Shale","year":"2009","journal-title":"Br Med Bull"},{"key":"R15-5-20240829","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1093\/ibd\/izz001","article-title":"Real-world Pattern of Biologic Use in Patients With Inflammatory Bowel Disease: Treatment Persistence, Switching, and Importance of Concurrent Immunosuppressive Therapy","volume":"25","author":"Chen","year":"2019","journal-title":"Inflamm Bowel Dis"},{"key":"R16-5-20240829","first-page":"523","article-title":"Rate of discontinuation and drug survival of biologic therapies in rheumatoid arthritis: A systematic review and meta-analysis of drug registries and health care databases","volume":"55","author":"Souto","year":"2016","journal-title":"Rheumatology (Oxford, England"},{"key":"R17-5-20240829","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1007\/s10067-017-3593-x","article-title":"Impact of prior biologic use on persistence of treatment in patients with psoriatic arthritis enrolled in the US Corrona registry","volume":"36","author":"Harrold","year":"2017","journal-title":"Clin Rheumatol"},{"key":"R18-5-20240829","first-page":"63","article-title":"Biologics in the management of ulcerative colitis-Comparative safety and efficacy of TNF-\u03b1 antagonists","volume":"11","author":"Fausel","year":"2015","journal-title":"Ther Clin Risk Manag"},{"key":"R19-5-20240829","first-page":"71","article-title":"Considering patient preferences when selecting anti-tumor necrosis factor therapeutic options","volume":"7","author":"Sylwestrzak","year":"2014","journal-title":"Am Health Drug Benefits"},{"key":"R20-5-20240829","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1111\/apt.13294","article-title":"Efficacy and safety of anti-TNF therapy in elderly patients with inflammatory bowel disease","volume":"42","author":"Lobaton","year":"2015","journal-title":"Aliment Pharmacol Ther"},{"key":"R21-5-20240829","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1002\/ibd.23026","article-title":"Older age is associated with higher rate of discontinuation of anti-TNF therapy in patients with inflammatory bowel disease","volume":"19","author":"Desai","year":"2013","journal-title":"Inflamm Bowel Dis"},{"key":"R22-5-20240829","doi-asserted-by":"crossref","first-page":"2257","DOI":"10.1097\/MIB.0b013e31828c8536","article-title":"Management of the elderly patients with inflammatory bowel disease: Practical considerations","volume":"19","author":"Katz","year":"2013","journal-title":"Inflamm Bowel Dis"},{"key":"R23-5-20240829","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1093\/ecco-jcc\/jjv059","article-title":"Inflammatory bowel disease and the elderly: A review","volume":"9","author":"Taleban","year":"2015","journal-title":"J Crohns Colitis"},{"key":"R24-5-20240829","doi-asserted-by":"crossref","first-page":"51","DOI":"10.4292\/wjgpt.v7.i1.51","article-title":"Elderly patients and inflammatory bowel disease","volume":"7","author":"Nimmons","year":"2016","journal-title":"World J Gastrointest Pharmacol Ther"},{"key":"R25-5-20240829","doi-asserted-by":"crossref","first-page":"1769","DOI":"10.1111\/j.1469-0691.2011.03680.x","article-title":"Viral infections associated with the clinical use of monoclonal antibodies","volume":"17","author":"Gentile","year":"2011","journal-title":"Clin Microbiol Infect"}],"container-title":["Saudi Journal of Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.4103\/sjg.sjg_336_21","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T19:08:03Z","timestamp":1787166483000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/sjg.sjg_336_21"}},"subtitle":["Real world experience"],"short-title":[],"issued":{"date-parts":[[2022,5]]},"references-count":25,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2022]]}},"URL":"https:\/\/doi.org\/10.4103\/sjg.sjg_336_21","relation":{},"ISSN":["1319-3767"],"issn-type":[{"value":"1319-3767","type":"print"}],"subject":[],"published":{"date-parts":[[2022,5]]}}}